Ewald van Dyk
Overview
Explore the profile of Ewald van Dyk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
1350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bakker N, Garner H, van Dyk E, Champanhet E, Klaver C, Duijst M, et al.
NPJ Breast Cancer
. 2025 Jan;
11(1):5.
PMID: 39843922
Cancer disrupts intratumoral innate-adaptive immune crosstalk, but how the systemic immune landscape evolves during breast cancer progression remains unclear. We profiled circulating immune cells in stage I-III and stage IV...
2.
Blomberg O, Spagnuolo L, Garner H, Voorwerk L, Isaeva O, van Dyk E, et al.
Cancer Cell
. 2022 Dec;
41(1):106-123.e10.
PMID: 36525971
Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research into the mechanisms underlying response to ICB has predominantly focused on T cells; however, effective immune responses...
3.
Shugay M, Bagaev D, Zvyagin I, Vroomans R, Crawford J, Dolton G, et al.
Nucleic Acids Res
. 2017 Oct;
46(D1):D419-D427.
PMID: 28977646
The ability to decode antigen specificities encapsulated in the sequences of rearranged T-cell receptor (TCR) genes is critical for our understanding of the adaptive immune system and promises significant advances...
4.
Iorio F, Knijnenburg T, Vis D, Bignell G, Menden M, Schubert M, et al.
Cell
. 2016 Jul;
166(3):740-754.
PMID: 27397505
Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature of cancer. Using this information to guide the development and application of therapies in the clinic is...
5.
van Dyk E, Hoogstraat M, Ten Hoeve J, Reinders M, Wessels L
Nat Commun
. 2016 Jul;
7:12159.
PMID: 27396759
The frequent recurrence of copy number aberrations across tumour samples is a reliable hallmark of certain cancer driver genes. However, state-of-the-art algorithms for detecting recurrent aberrations fail to detect several...
6.
Schouten P, Grigoriadis A, Kuilman T, Mirza H, Watkins J, Cooke S, et al.
Mol Oncol
. 2015 Apr;
9(7):1274-86.
PMID: 25825120
Breast cancers with BRCA1 germline mutation have a characteristic DNA copy number (CN) pattern. We developed a test that assigns CN profiles to be 'BRCA1-like' or 'non-BRCA1-like', which refers to...
7.
Massink M, Kooi I, van Mil S, Jordanova E, Ameziane N, Dorsman J, et al.
Mol Oncol
. 2015 Jan;
9(4):877-88.
PMID: 25616998
Introduction: BRCA1-mutated breast carcinomas may have distinct biological features, suggesting the involvement of specific oncogenic pathways in tumor development. The identification of genomic aberrations characteristic for BRCA1-mutated breast carcinomas could...
8.
Schouten P, van Dyk E, Braaf L, Mulder L, Lips E, de Ronde J, et al.
Breast Cancer Res Treat
. 2013 May;
139(2):317-27.
PMID: 23670131
Previously, we employed bacterial artificial chromosome (BAC) array comparative genomic hybridization (aCGH) profiles from BRCA1 and -2 mutation carriers and sporadic tumours to construct classifiers that identify tumour samples most...
9.
van Dyk E, Reinders M, Wessels L
Nucleic Acids Res
. 2013 Mar;
41(9):e100.
PMID: 23476020
Tumor formation is partially driven by DNA copy number changes, which are typically measured using array comparative genomic hybridization, SNP arrays and DNA sequencing platforms. Many techniques are available for...